logo

INFLAMMATION, CANCER & IMMUNOTHERAPY EUROPEAN JOINT MASTER

Sector: Education • Location: Spain

Source: EU Funding & Tenders Portal

Project
Ended

The Inflammation, Cancer & Immunotherapy (ICI) European Joint Master will aim to introduce students to understand the different pathways in which cancer cells and the immune system interact, to learn how cancer immunotherapies are developed, as well as to learn cutting edge advancement of treatments that are either currently used or are under clinical research to prolong the lives of cancer patien

Project Information FAQ

Project Information

4 Q
The project “INFLAMMATION, CANCER & IMMUNOTHERAPY EUROPEAN JOINT MASTER” is an infrastructure initiative in the Education sector, located in Spain. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

The Inflammation, Cancer & Immunotherapy (ICI) European Joint Master will aim to introduce students to understand the different pathways in which cancer cells and the immune system interact, to learn how cancer immunotherapies are developed, as well as to learn cutting edge advancement of treatments that are either currently used or are under clinical research to prolong the lives of cancer patients. The course will provide to biomedical or life scientists to acquire an extensive knowledge and key skills relating a deep understanding of inflammation and other immune effector mechanisms, their relation to cancer as well as the fundamental bases of cancer biology and its application to the treatment of cancer. ICI European Joint Master will provide an in-depth understanding of the molecular targets at which the different classes of immunotherapy drugs are aimed, as well as their evolution. Cancer is increasing worldwide, and in a decade, there are expected to be >22M new cases per year. Within this full-time 2 year (120 ECTS) European Joint Master programme the students will be trained to be the next generation of highly qualified interdisciplinary professionals who can be immediately implicated in the design, development and implementation of immunotherapy for cancer, positively impacting on the global burden of cancer. The programme will be delivered by world leaders with internationally renowned research groups at the forefront of inflammation, cancer and immunotherapy research across three leading European universities: University of Murcia (Spain), University of Rouen Normandy (France) and University of Ferrara (Italy). The teachers will also include clinical staff who are involved in the delivery of immunotherapy to patients, as well as in early phases of clinical trials for the study of novel immunotherapy approaches as chimeric antigen receptor T cells. For these goals, ICI will have key non-academic collaborations with hospitals, research centres and industry

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data